PMID: 37697May 1, 1979

Therapeutical significance of clopimozide in the treatment of chronic psychotic patients

Acta Psychiatrica Scandinavica
H J De CuyperW R Mulder

Abstract

This report, which concerns both an open and a double-blind study, describes the activity profile and optimum daily dose of clopimozide (R 29 764) investigated in 40 chronic psychotic patients. The results of the open study indicated that clopimozide represents an equal, if not superior, choice versus the other neuroleptics which the patients had been receiving before the open study. Patients sought more contact with those surrounding them, were less preoccupied with their delusions and hallucinations, and showed a better adapted social behaviour. However, these results were not confirmed by the data from the double-blind study-showing that clopimozide was less superior to the placebo than expected on the basis of the open trial. Two hypotheses are advanced to explain this discrepancy: first, the difference in investigational method and second, possible over-dosage of the drug at an average optimum daily dose of 13.95 mg.

Citations

Mar 15, 1975·Life Sciences·L J MichielsP A Janssen
Dec 18, 1971·British Medical Journal·H M Van PraagR van Schilfgaarden
Aug 7, 1971·British Medical Journal·M AsbergD Tuck
Sep 1, 1967·The British Journal of Psychiatry : the Journal of Mental Science·A D HarrisP J Willems
Dec 1, 1968·Community Mental Health Journal·T J Kiresuk, R E Sherman

Related Concepts

Antipsychotic Effect
Clopimozide
Antipsychotic Agents
Drug Evaluation
Clinical Trials
Incisors, Fused Mandibular
Psychotic Disorders
Factor Construct Rating Scales (Fcrs)
Double-Blind Method
Schizophreniform Disorders

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here